Zevra Therapeutics shares rose 19% after partnering with GeneDx to expand exome sequencing access for Niemann-Pick Disease type C, aiming to improve early diagnosis and treatment.

Zevra Therapeutics shares jumped 19% to $10.83 on Tuesday after announcing a partnership with GeneDx to expand access to exome sequencing for Niemann-Pick Disease type C (NPC), a rare genetic disorder. The collaboration aims to improve early diagnosis and clinical management by increasing availability of genetic testing across the U.S. The move follows Zevra’s reported profitability in 2025, driven by strong sales of its NPC treatment, MIPLYFFA.